Zohar J, Mueller E A, Insel T R, Zohar-Kadouch R C, Murphy D L
Laboratory of Clinical Science, National Institute of Mental Health, Bethesda, MD 20892.
Arch Gen Psychiatry. 1987 Nov;44(11):946-51. doi: 10.1001/archpsyc.1987.01800230026006.
To examine the "serotonin hypothesis" of obsessive-compulsive disorder (OCD), we studied the behavioral and neuroendocrine effects of metachlorophenylpiperazine (mCPP), a serotonergic agonist, in patients with OCD and healthy controls. Twelve patients and 20 controls were given a single dose of 0.5 mg/kg of mCPP, administered orally under double-blind, placebo-controlled, random-assignment conditions. Following mCPP, but not following placebo, patients with OCD experienced a transient but marked exacerbation of obsessive-compulsive symptoms. Moreover, compared with healthy controls, patients exhibited greater other behavioral (but not endocrinologic or thermal) changes after mCPP. These findings are consistent with a special role for the neurotransmitter serotonin in OCD psychopathology.
为检验强迫症（OCD）的“血清素假说”，我们研究了血清素能激动剂间氯苯哌嗪（mCPP）对强迫症患者和健康对照者的行为及神经内分泌影响。12名患者和20名对照者在双盲、安慰剂对照、随机分配条件下口服单剂量0.5mg/kg的mCPP。服用mCPP后，而非服用安慰剂后，强迫症患者出现强迫症状短暂但明显的加重。此外，与健康对照者相比，患者在服用mCPP后出现了更大的其他行为变化（但不是内分泌或体温变化）。这些发现与神经递质血清素在强迫症精神病理学中的特殊作用相一致。
